NCT02472717View on ClinicalTrials.gov

Psoriatic Arthritis Treated With Liraglutide Therapy: a QUality of Life and Efficacy Study

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

May 31, 2015

Primary Completion Date

October 31, 2016

Study Completion Date

October 31, 2016

Conditions
Psoriatic ArthritisPsoriasisImpaired Glucose ToleranceType 2 Diabetes
Interventions
DRUG

liraglutide

Liraglutide 0.6mg sc daily for 1 week, 1.2mg sc daily for 11 weeks

OTHER

Placebo

Placebo sc daily for 12 weeks, volume titration at week 2 to mirror liraglutide arm

Trial Locations (1)

M5T 2S8

Toronto Western Hospital, The Centre for Prognosis Studies in the Rheumatic Diseases (CPSRD), University of Toronto, Toronto

Sponsors

Collaborators (1)

Novo Nordisk A/S
All Listed Sponsors
collaborator

Novo Nordisk A/S

INDUSTRY

lead

University Health Network, Toronto

OTHER